MET and non-small cell lung carcinoma: The antitumour activity of c-MET inhibitors has been evaluated in the treatment of NSCLC in preclinical and clinical trials, and the combined use of EGFR-TKIs and c-MET inhibitors may be a promising treatment option for EGFR-TKI-naive and EGFR-TKI-resistant NSCLC patients 61.